Gland Pharma Limited Cash Flow-to-Debt Ratio
Gland Pharma Limited cash flow-to-debt ratio. Gland Pharma Limited (GLAND) has a Cash Flow-to-Debt Ratio of 0.27x as of September 2025, meaning its operating cash flow of Rs5.93 Billion could theoretically repay 0% of its total liabilities (Rs22.37 Billion) in one year. Check GLAND cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Gland Pharma Limited (2017–2026)
Cash flow-to-debt ratio of Gland Pharma Limited from 2017 to 2026. Historical debt coverage capacity for Gland Pharma Limited across 10 annual periods. Check how aggressively does Gland Pharma Limited reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Gland Pharma Limited Cash Flow-to-Debt Ratio by Year (2017–2026)
Gland Pharma Limited cash flow-to-debt ratio by year from 2017 to 2026. Year-by-year debt coverage analysis for Gland Pharma Limited. For the full cash flow conversion analysis, see how efficiently does Gland Pharma Limited generate cash.
| Year | CF-to-Debt Ratio | Operating CF (INR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | 0.57x | Rs12.31 Billion | Rs21.53 Billion | ▲ +29.7% |
| 2025 | 0.44x | Rs9.15 Billion | Rs20.74 Billion | ▼ -14.3% |
| 2024 | 0.51x | Rs9.97 Billion | Rs19.37 Billion | ▲ +15.7% |
| 2023 | 0.44x | Rs3.64 Billion | Rs8.19 Billion | ▼ -62.0% |
| 2022 | 1.17x | Rs7.91 Billion | Rs6.76 Billion | ▲ +14.6% |
| 2021 | 1.02x | Rs6.05 Billion | Rs5.93 Billion | ▼ -36.0% |
| 2020 | 1.59x | Rs7.01 Billion | Rs4.40 Billion | ▲ +469.1% |
| 2019 | 0.28x | Rs1.85 Billion | Rs6.62 Billion | ▼ -28.1% |
| 2018 | 0.39x | Rs2.02 Billion | Rs5.19 Billion | ▼ -68.6% |
| 2017 | 1.24x | Rs4.76 Billion | Rs3.84 Billion | — |